Quick Answer
Tenaya Therapeutics, Inc. reported Diluted EPS of $0.59 per share (loss) for fiscal year 2025.
Tenaya Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.59 | +55.0% |
| 2024 | -$1.31 | +22.0% |
| 2023 | -$1.68 | +39.1% |
| 2022 | -$2.76 | +32.7% |
| 2021 | -$4.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.12 | +60.0% | +14.3% |
| June 30, 2025 | -$0.14 | +58.8% | +41.7% |
| March 31, 2025 | -$0.24 | +40.0% | +20.0% |
| September 30, 2024 | -$0.30 | +23.1% | +11.8% |
| June 30, 2024 | -$0.34 | +24.4% | +15.0% |
| March 31, 2024 | -$0.40 | +7.0% | -2.6% |
| September 30, 2023 | -$0.39 | +47.3% | +13.3% |
| June 30, 2023 | -$0.45 | +34.8% | -4.7% |
- Tenaya Therapeutics, Inc. showed an increase of +55.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Tenaya Therapeutics, Inc.’s diluted eps has grown by 85.6% (from $4.10 per share (loss) to $0.59 per share (loss)).
- The most recent figure is from Tenaya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: